Free Trial
NYSE:ENOV

Enovis (ENOV) Stock Price, News & Analysis

Enovis logo
$31.41 +1.91 (+6.47%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$31.44 +0.04 (+0.12%)
As of 08/22/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enovis Stock (NYSE:ENOV)

Key Stats

Today's Range
$29.84
$31.75
50-Day Range
$25.74
$35.94
52-Week Range
$25.47
$49.83
Volume
908,166 shs
Average Volume
1.22 million shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.00
Consensus Rating
Buy

Company Overview

Enovis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

ENOV MarketRank™: 

Enovis scored higher than 89% of companies evaluated by MarketBeat, and ranked 120th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Enovis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Enovis' stock forecast and price target.
  • Earnings Growth

    Earnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enovis is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enovis is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enovis has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Enovis' valuation and earnings.
  • Percentage of Shares Shorted

    12.30% of the float of Enovis has been sold short.
  • Short Interest Ratio / Days to Cover

    Enovis has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Enovis has recently decreased by 7.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enovis does not currently pay a dividend.

  • Dividend Growth

    Enovis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.30% of the float of Enovis has been sold short.
  • Short Interest Ratio / Days to Cover

    Enovis has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Enovis has recently decreased by 7.40%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Enovis has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Enovis this week, compared to 6 articles on an average week.
  • Search Interest

    1 people have searched for ENOV on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enovis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $74,275.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Enovis is held by insiders.

  • Percentage Held by Institutions

    98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enovis' insider trading history.
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Stock News Headlines

Enovis (NYSE:ENOV) CFO Buys $74,275.00 in Stock
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
Enovis (NYSE:ENOV) Shares Gap Up - Time to Buy?
Wells Fargo Sticks to Its Buy Rating for Enovis (ENOV)
See More Headlines

ENOV Stock Analysis - Frequently Asked Questions

Enovis' stock was trading at $43.88 at the start of the year. Since then, ENOV shares have decreased by 28.4% and is now trading at $31.4080.

Enovis Corporation (NYSE:ENOV) posted its earnings results on Thursday, August, 7th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.05. The firm's revenue was up 7.5% compared to the same quarter last year.
Read the conference call transcript
.

Enovis' top institutional investors include DAVENPORT & Co LLC (4.98%), Hood River Capital Management LLC (3.04%), River Road Asset Management LLC (2.52%) and Boston Partners (2.42%). Insiders that own company stock include Matthew L Trerotola, Phillip Benjamin (Ben) Berry, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner.
View institutional ownership trends
.

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
8/07/2025
Today
8/24/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:ENOV
CIK
1420800
Employees
7,367
Year Founded
N/A

Price Target and Rating

High Price Target
$58.00
Low Price Target
$41.00
Potential Upside/Downside
+62.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
11.26
P/E Growth
N/A
Net Income
-$825.49 million
Net Margins
-37.80%
Pretax Margin
-36.51%
Return on Equity
6.78%
Return on Assets
3.73%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
2.25
Quick Ratio
1.15

Sales & Book Value

Annual Sales
$2.11 billion
Price / Sales
0.85
Cash Flow
$19.15 per share
Price / Cash Flow
1.64
Book Value
$45.15 per share
Price / Book
0.70

Miscellaneous

Outstanding Shares
57,160,000
Free Float
55,617,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
1.70
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:ENOV) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners